This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2019
ASCO GU 2019 Prostate Cancer
ASCO GU 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2019 Prostate Cancer
Viewing 181-200 of 11532 articles
ASCO 2024: Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
ASCO 2024: Utility of ctDNA Burden as a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + Enzalutamide as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO 2024: Comparison of TKI and CPI Strategies as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma: Real-World Outcome Data from the German Research Platform CARAT
ASCO 2024: Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2
ASCO 2024: 68Ga-PSMA PET/CT Response and Clinical Outcomes in Patients Treated with Enzalutamide as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer: Results of a Prospective Study
ASCO 2024: Lenvatinib plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and Subsequent Therapy in the CLEAR Trial
ASCO 2024: Changes in Treatment Patterns and Attrition Rates in Patients with Metastatic Clear Cell Renal Cell Carcinoma
ASCO 2024: CYP11A1 Inhibitor MK-5684 Versus Next-Generation Hormonal Agent Switch in Patients with Metastatic Castration-Resistant Prostate Cancer After One Prior Next-Generation Hormonal Agent: Phase 3 MK-5684-004 Study
ASCO 2024: A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy (RP) in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)
ASCO 2024: Randomized PROSTATE-IQ Trial to Reduce ADT Treatment Burden for Patients with Biochemical Recurrence After Prostatectomy
ASCO 2024: Matched Tissue and Circulating Tumor DNA (ctDNA) Analysis in Renal Cell Carcinoma (RCC): Results from a Multimodal Real-World Database
ASCO 2024: Impact of Mental Health Illness Prior to Prostate Cancer Diagnosis on Treatment Received and Prostate Cancer Outcomes
ASCO 2024: ProstACT GLOBAL: A Phase 3 Study of Best Standard of Care with and Without 177Lu-DOTA-Rosopatamab (TLX591) for Patients with PSMA Expressing mCRPC Progressing Despite Prior Treatment with a Novel Androgen Axis Drug
ASCO 2024: Enfortumab Vedotin plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology: A Phase II Study
ASCO 2024: Effect of Concomitant Medications on Treatment Response and Survival in Non-Metastatic Castrate Resistant Prostate Cancer: Secondary Analysis of the SPARTAN Trial
ASCO 2024: Association Between Prostate-Specific Antigen (PSA) Level 0.2 ng/mL and Risk of Radiological Progression in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Follow-up Analysis of ARAMIS
ASCO 2024: Veterans Affairs Seamless Phase II/III Randomized Trial of Standard Systemic Therapy with or Without PET-Directed Local Therapy for Oligometastatic Prostate Cancer (VA STARPORT)
ASCO 2024: CYP11A1 Inhibitor MK-5684 Versus Next-Generation Hormonal Agent Switch in Patients with Metastatic Castration-Resistant Prostate Cancer After Next-Generation Hormonal Agent and Taxane-Based Chemotherapy: Phase 3 MK-5684-003 Trial
ASCO 2024: Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches
ASCO 2024: Discussion: Living Your Best Life on Treatment
5
6
7
8
9
10
11
12
13
14
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free